Scleroderma

Esophageal Dysphagia Predicts PPI-Partial Response GERD in Systemic Sclerosis

A team of investigators sought to determine the prevalence of proton pump inhibitor-partial response gastroesophageal reflux disease in patients with systemic sclerosis.

Sitaxsentan Designated Orphan Drug for Systemic Sclerosis

The FDA has granted Orphan Drug designation to TMB-003 (Timber Pharmaceuticals) for the treatment of systemic sclerosis.

Obstetric Complications Common Among Women Who Develop Systemic Sclerosis

Researchers evaluated obstetric complications in women with a systemic sclerosis diagnosis vs the general obstetric population.

Revised CRISS Developed to Improve dcSSc Study Outcome Measures

The performance of 5 core set measure in ACR-CRISS in recent trials was explored, and their ability to discern the active medication group from placebo in patients with diffuse cutaneous systemic sclerosis (dcSSc), was assessed.

Progressive ILD Trends in Systemic Sclerosis-Associated ILD

Close monitoring of patients with systemic sclerosis-associated interstitial lung disease and awareness of the variable course of progression is highly important in considering when to initiate treatment.

Data Support Safety, Efficacy of Abatacept in Early Diffuse Cutaneous Systemic Sclerosis

In this open-label extension study, researchers reported on the safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis.

Nintedanib Clinically Beneficial in Progression of Systemic Sclerosis-Associated Interstitial Lung Disease

Study authors analyzed the effects of nintedanib on changes in forced vital capacity and other measures of progression in systemic sclerosis-associated interstitial lung disease.

Antifibrotic Therapy Gets Orphan Drug Status for Systemic Sclerosis

ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.

British Society for Rheumatology Releases Consensus-Based Recommendations for Juvenile SSc Management

The British Society for Rheumatology released consensus-based recommendations for the management of juvenile systemic sclerosis.

Pulmonary Function Tests May Underdiagnose Interstitial Lung Disease in Juvenile Systemic Sclerosis

Study authors determined the performance of pulmonary screening vs HRCT in detecting interstitial lung disease in juvenile SSc.